UroGen Pharma
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompa...
Latest News
8 days ago · seekingalpha.com
UroGen: Opportunity Builds As Rough Patch Gets BrutalUroGen Pharma is rated a 'Buy' at a depressed ~$1.21B market cap, with potential for ~65% upside in 2027. Management has established a promising setup, featuring two approved products—Jelmyto and Zusdori—leveraging the proprietary RT Gel delivery system. Jelmyto's sales have stalled below initial expectations, while Zusdori is positioned for significant growth and could drive future upside.
12 days ago · marketbeat.com
Urogen Pharma Q3 Earnings Call HighlightsUrogen Pharma NASDAQ: URGN reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow. The company said it expects to achieve profitability and generate positive cash flow in the fourth quarter of 2026.
12 days ago · fool.com
The Gel That Became a BusinessZosturi quarterly net product revenue reached $68 million. Repeat prescribers expanded to 50% of total Zosturi writers.
12 days ago · seekingalpha.com
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call TranscriptUroGen Pharma Ltd. ( URGN ) Q3 2026 Earnings Call November 4, 2026 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Leland Gershell - Oppenheimer & Co. Inc., Research Division Tara Bancroft - TD Cowen, Research Division Raghuram Selvaraju - H.C.
13 days ago · zacks.com
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue EstimatesUrogen Pharma (URGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $0.69 per share a year ago.
13 days ago · globenewswire.com
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and HighlightsZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027 Announced first patient dosed in the UGN-501 Phase 1 trial Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
14 days ago · globenewswire.com
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation ConferencePRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
15 days ago · globenewswire.com
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerPhase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
20 days ago · globenewswire.com
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
29 days ago · globenewswire.com
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBCPRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-103 (mitomycin) for intravesical solution for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove URGN